

Horizon Europe – Cluster 1 HEALTH: Workprogramme 2026/2027 (Pillar 2)

Topics List

Call Identifier	Topic	Instrument / Seite im Workprogramm	Budget pro Projekt in Mio EUR	Budget pro Topic in Mio EUR	Anzahl Projekte	Einreichfrist 1.Stufe/ Vollantrag	Einreichfrist 2. Stufe
DESTINATION	Staying healthy in a rapidly changing society						
HORIZON-HLTH-2026-01-STAYHLTH-02	Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people	RIA ¹⁾ / S.27	9-10	20,6	2	16.04.2026	n/a
HORIZON-HLTH-2026-01-STAYHLTH-03	Building public trust and outreach in the life sciences	CSA / S. 32	1,5-1,9	1,9	1	16.04.2026	n/a
HORIZON-HLTH-2027-01-STAYHLTH-01	Addressing disabilities through the life course to support independent living and inclusion	RIA ¹⁾ / S.36	6-8	39,3	5	13.04.2027	n/a
DESTINATION	Living and working in a health-promoting environment						
HORIZON- HLTH-2026-01-ENVHLTH-01	Towards a better understanding and anticipation of the impacts of climate change on health	RIA / S.41	ca. 7-8	55	7	16.04.2026	n/a
HORIZON-HLTH-2026-01-ENVHLTH-04	Towards climate resilient, prepared and carbon neutral populations and healthcare systems	RIA / S. 43	ca. 7-8	45	6	16.04.2026	n/a
HORIZON-HLTH-2026-01-ENVHLTH-05	Support for a multilateral initiative on climate change and health research	CSA / S. 52	3	Around 3	1	16.04.2026	n/a
HORIZON- HLTH-2027-01-ENVHLTH-02	Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change	RIA / S.54	10-11	45	4	13.04.2027	n/a

HORIZON- HLTH-2027-01-ENVHLTH-MISSCLIMA-03	Tools and technologies to support health adaptation to climate change	PCP / S.59	4-5	20	7	13.04.2027	n/a
DESTINATION	Tackling diseases and reducing disease burden						
HORIZON-HLTH-2026-01-DISEASE-02	Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults	RIA / S. 66	Around 8	44,2	6	16.04.2026	n/a
HORIZON-HLTH-2026-01-DISEASE-03	Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions	RIA / S. 69	6-8	39,3	5	16.04.2026	n/a
HORIZON-HLTH-2026-01-DISEASE-04	Development of novel vaccines for viral pathogens with epidemic potential	RIA / S.73	9-11	44,2	5	16.04.2026	n/a
HORIZON-HLTH-2026-01-DISEASE-09	Multisectoral approach to tackle chronic noncommunicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)	RIA / S.76	3-4	9,8	3	16.04.2026	n/a
HORIZON-HLTH-2026-01-DISEASE-11	Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways	RIA / S.81	6-7	39,3	6	16.04.2026	n/a
HORIZON-HLTH-2026-01-DISEASE-15	Scaling up innovation in cardiovascular health	CSA / S.96	Around 1,9	1,9	1	16.04.2026	n/a
HORIZON-HLTH-2027-01-DISEASE-05	Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential	RIA / S. 104	9-11	44,2	5	13.04.2027	n/a
HORIZON-HLTH-2027-01-DISEASE-06	Development of monoclonal antibodies to prevent and treat infections from Flaviviruses	RIA / S.107	9-10	37,3	4	13.4.2027	n/a

HORIZON-HLTH-2027-01-DISEASE-07	Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses	RIA / S.110	9-10	37,3	4	13.04.2027	n/a
HORIZON-HLTH-2027-01-DISEASE-08	Development of innovative antimicrobials against pathogens resistant to antimicrobials	RIA / S.113	8-10	44,2	5	13.04.2027	n/a
HORIZON-HLTH-2027-01-DISEASE-10	Prevention and management of chronic noncommunicable diseases in children and young people (GACD)	RIA / S116	3-4	11,8	3	13.04.2027	n/a
HORIZON-HLTH-2027-02-DISEASE-01-two-stage	Innovative healthcare interventions for non-communicable diseases	RIA /S.99	7-8	63,8	8	13.04.2027	22.09.2027
HORIZON-HLTH-2027-02-DISEASE-14- two-stag	Clinical trials for advancing innovative interventions for neurodegenerative diseases	RIA /S.121	Around 10	39,3	4	13.04.2027	22.09.2027
Call Identifier	CALL – Partnerships in Health (2026/1)						
HORIZON-HLTH-2026-02- DISEASE-12	European Partnership on Rare Diseases (ERDERA) (Phase 2)	COFUND/ S.85	42,6 in 2026 /48,7 in 2027	Around 91,3	1	15.09.2026	n/a
Call Identifier	CALL – Partnerships in Health (2026/2)						
HORIZON-HLTH-2026-03- DISEASE-13	European Partnership for Pandemic Preparedness (Phase 2)	COFUND / S.90	30 in 2026 / 33 in 2027	Around 63	1	13.04.2027	n/a
DESTINATION	Ensuring equal access to innovative, sustainable and high-quality health care						
HORIZON-HLTH-2026-01-CARE-01	Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches	PPI / S.129	3-8	24,5	4	16.04.2026	n/a
HORIZON-HLTH-2026-01-CARE-03	Identifying and addressing low-value care in health and care systems	RIA / S.133	Around 10	38	4	16.04.2026	n/a

HORIZON-HLTH-2027-01-CARE-02	Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications	RIA / S. 140	8-10	38	4	13.04.2027	n/a
Call Identifier	CALL – Partnerships in Health (2026/3)						
HORIZON-HLTH-2026-04-CARE-04	Enhancing and enlarging the European Partnership on Personalised Medicine (EP PerMED) (Top-up)	COFUND / S. 136	9,8 in 2026	9,8	1	16.04.2026	n/a
DESTINATION	Developing and using new tools, technologies and digital solutions for a healthy society						
HORIZON-HLTH-2026-01-TOOL-03	Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing	RIA / S.148	5-8	49	7	16.04.2026	n/a
HORIZON-HLTH-2026-01-TOOL-05	Pilot actions for follow-on funding: Leveraging EUfunded collaborative research in regenerative medicine	IA / S.152	6-8	29,5	4	16.04.2026	n/a
HORIZON-HLTH-2026-01-TOOL-06	Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices	CSA / S.155	Around 2,9	2,9	1	16.04.2026	n/a
HORIZON-HLTH-2026-01-TOOL-07	Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)	CSA / S.158	Around 3,9	3,9	1	16.04.2026	n/a
HORIZON-HLTH-2027-02-TOOL-01-twostage	Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic noncommunicable diseases	RIA /S.162	6-8	44,2	6	13.04.2027	22.09.2027
HORIZON-HLTH-2027-03-TOOL-02	Advancing bio-printing of living cells for regenerative medicine	RIA / S.166	7-10	39,3	4	22.09.2027	n/a

HORIZON-HLTH-2027-03-TOOL-04	Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis	RIA / S.169	10-12	39,3	4	22.09.2027	n/a
HORIZON-HLTH-2027-03-TOOL-08	Towards Artificial General Intelligence (AGI) for healthcare	CSA / S.173	Around 2,9	2,9	4	22.09.2027	n/a
DESTINATION	Maintaining an innovative, sustainable, and competitive EU health industry						
HORIZON-HLTH-2026-01-IND-03	Regulatory science to support translational development of patient-centred health technologies	RIA / S180.	4-6	19,6	4	16.04.2026	n/a
HORIZON-HLTH-2027-01-IND-01	Development of cell-free protein synthesis platforms for discovery and/or production of biologicals	RIA / S.184	6-8	24,5	4	13.04.2027	n/a
HORIZON-HLTH-2027-02-IND-02-two-stage	Portable and versatile Point-of-care diagnostics	IA / S. 187	5-7	39,3	6	13.04.2027	22.9.2027

Horizon Europe: MISSION CANCER – Workprogramme Missions 2026 / 2027 (Pillar 2) Topics List

Call Identifier	Topic	Instrument / Seite im Workprogramm	Budget pro Projekt in Mio EUR	Budget pro Topic in Mio EUR	Anzahl Projekte	Einreichfrist 1.Stufe/ Vollantrag	Einreichfrist 2. Stufe
HORIZON-MISS-2026-02-CANCER-01	Virtual Human Twin (VHT) Models for Cancer Research	RIA / S.67	8-9	35	4	15.09.2026	n/a
HORIZON-MISS-2026-02-CANCER-02	Microbiome for early cancer prediction before the onset of disease	RIA / S.70	15	15	1	15.09.2026	n/a

HORIZON-MISS-2026-02-CANCER-03	Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers	RIA / S.73	7-8	22,19	3	15.09.2026	n/a
HORIZON-MISS-2026-02-CANCER-04	Earlier and more precise palliative care	RIA / S.76	5	15	3	15.09.2026	n/a
HORIZON-MISS-2026-02-CANCER-05	Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC)	IA / S. 78	7	7	1	15.09.2026	n/a
HORIZON-MISS-2026-02-CANCER-06	Development of a research capacity building programme on cancer with and for Ukraine	CSA / S.81	5	5	1	15.09.2026	n/a
HORIZON-MISS-2026-02-CANCER-07	Improve the Quality of Life of older cancer patients	RIA / S.84	5-6	25	5	15.09.2026	n/a
HORIZON-MISS-2027-02-CANCER-01	Leveraging functional genomics to reveal novel targets for cancer treatment ⁵⁾	RIA / S.87	7-8	32,32	4	21.09.2027	n/a
HORIZON-MISS-2027-02-CANCER-02	Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers ⁵⁾	IA /S.89	7-10	20	3	21.09.2027	n/a
HORIZON-MISS-2027-02-CANCER-03	Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes ⁵⁾	RIA / S.93	7-9	24	3	21.09.2027	n/a
HORIZON-MISS-2027-02-CANCER-04	Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research	RIA / S.95	5-7	10	3	21.09.2027	n/a

HORIZON-MISS-2027-02-CANCER-05	Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines ⁵⁾	PCP / S.98	8-10	26	3	21.09.2027	n/a
HORIZON-MISS-2027-02-CANCER-06	Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies ⁵⁾	CSA / S.100	3	3	1	21.09.2027	n/a

- 1) RIA: Research and Innovation Action: Ziel ist das Schaffen von neuem Wissen und Kenntnissen zur Umsetzung in Produkte, Verfahren, Technologien und Dienstleistungen sowie die Untersuchung der Machbarkeit. Förderquote: 100 %. Mindestteilnehmerzahl: Drei Partner aus drei unterschiedlichen EU-Mitgliedstaaten oder assoziierten Staaten. Mindestens einer der Partner muss aus einem EU-Mitgliedstaat stammen.
- 2) IA: Innovation Action: Ziele des Förderinstruments sind die Entwicklung von Plänen oder Anlagen für neue oder verbesserte Produkte, Prozesse und Dienstleistungen. Zudem steht hier die Umsetzung am Markt und die groß angelegte Produktvalidierungen in operativer Umgebung im Mittelpunkt. Forschung ist nur wenig bis gar nicht möglich. Förderquote: 70 % (Nicht-gewinnorientierte Einrichtungen können 100 % Förderung erhalten.) Mindestteilnehmerzahl: Drei Partner aus drei unterschiedlichen EU-Mitgliedstaaten oder assoziierten Staaten. Mindestens einer der Partner muss aus einem EU-Mitgliedstaat stammen.
- 3) CSA: Cooperation and Support Action: Bei diesem Förderinstrument ist die Koordinierung oder Unterstützung von Forschungstätigkeiten und Forschungsstrategien sowie die Unterstützung über-greifender politischer Interessen das Ziel. Förderquote: 100 %. CSA können von einem einzelnen Partner beantragt werden, werden jedoch meist in Konsortien umgesetzt. Die Beteiligung von Partnern aus Drittstaaten ist nur in Ausnahmefällen möglich.
- 4) COFUND: Cofinanced Action: Europäische Partnerschaften sind Verbünde der Europäischen Union, vertreten durch die Europäische Kommission, und privaten und/oder öffentlichen Partnern. Die Zusammenarbeit mit diesen Partnern soll einen besonderen und ergänzenden Mehrwert für Forschung & Innovation in Europa erzeugen, der von Projekten, die unter Horizon Europe gefördert werden, nicht erreicht werden kann.
- 5) Link noch nicht verfügbar